COL6A2 and neoplasm: One approach is the direct inhibition of the interaction, either at the receptor level using agents targeting β1 integrins or, more specifically, by disrupting the COL6A2-integrin interface with monoclonal antibodies or decoy peptides once tumor-selective epitopes are defined 46-49.